Corporate News

From October 25th to 26th, 2025, the 2025 Annual Conference of the Physician Health Management and Physician Health Insurance Professional Committee of the Chinese Medical Doctor Association was successfully held in Zhengzhou with the theme of "Traditional Chinese Medicine Wisdom Governance · Science and Technology Innovation Empowerment, Central Plains Health Discussion · Practical Competition". Authoritative experts in the field of health management across the country gathered to have in-depth discussions on the hot and difficult issues in the industry, providing new ideas for the high-quality development of the health management cause. Among them, the "Chronic Disease Health Management and Quality Control Forum", jointly hosted by Professor An Shujie from Xijing Hospital of Air Force Medical University and Professor Lin Weihong from the First Affiliated Hospital of Wenzhou Medical University, became the focus of the conference due to its focus on the clinical value of oxidized low-density lipoprotein (OxLDL).

|Professor Zhang Daqing's special lecture

In the special report titled "Exploration of the Clinical Value of Oxidized Low-density Lipoprotein as a Drug Intervention Target for ASCVD" by Professor Zhang Daqing from Shengjing Hospital Affiliated to China Medical University, the core position of OxLDL in atherosclerotic cardiovascular disease (ASCVD) was systematically expounded. The report indicates that OxLDL is involved in the process of atherosclerotic lesions through multiple pathogenesis mechanisms. It is not only a key triggering factor of this process but also the main residual risk after cholesterol management. Studies have shown that OxLDL is closely related to multiple metabolic risk factors and ASCVD events, and can be used as an emerging indicator or risk-enhancing factor for ASCVD risk assessment. It is worth mentioning that probucol, a lipid-regulating drug with antioxidant effects, provides evidence-based support for the oxidative stress theory and also opens up new ideas for OxLDL intervention and ASCVD prevention and control.

|Professor Chen Weiqi's special lecture

Professor Chen Weiqi from Beijing Tiantan Hospital, Capital Medical University, delivered a presentation titled "Research Progress of Oxidized Low-density Lipoprotein in the Field of Stroke", systematically reviewing the latest research progress of OxLDL in the prevention and treatment of stroke. The report points out that the current burden of stroke disease is continuously rising. Clarifying its core pathogenic mechanism is a key prerequisite for improving the effectiveness of prevention and treatment. Studies have confirmed that OxLDL is an important independent risk factor for ischemic stroke. Its elevated level is significantly positively correlated with the risk of stroke recurrence, the incidence of combined vascular events, and adverse functional outcomes, providing an important reference indicator for stroke risk stratification and prognosis assessment. Professor Chen further emphasized that intervention strategies targeting OXLDL-related pathways, especially innovative treatment regimens that reduce OxLDL levels by regulating antioxidant stress responses, have demonstrated clear clinical application potential in previous studies, providing new ideas and directions for breaking through existing bottlenecks in stroke prevention and treatment.

From Professor Zhang Daqing's outlook on the prospects of OxLDL as a drug intervention target for ASCVD to Professor Chen Weiqi's in-depth research and analysis in the field of stroke, although the cutting-edge achievements of the two experts focus on different disease areas, they clearly point to the same core: the clinical value of OxLDL has accelerated from an academic and scientific research consensus to a new stage of clinical transformation and application. As a practitioner deeply engaged in the field of OxLDL detection, our company is well aware that precise detection technology is precisely the key bridge connecting this scientific research consensus with clinical practice. For many years, Jinci Biotechnology has been committed to transforming the cutting-edge research achievements of experts into clinically usable data through stable and reliable reagent products, providing strong support for precise screening, risk assessment and treatment monitoring of chronic diseases.

This in-depth exchange with Zhongyuan Lunjian has further strengthened Jinci Biotech's determination to empower clinical practice through technological innovation. In the future, our company will continue to drive the upgrading of detection technology through innovation, and with a pragmatic attitude, deeply explore clinical needs, injecting more solid technological impetus into the Healthy China initiative.